The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The study treatment uses three medicines together: venetoclax, standard 3+7 chemotherapy, and midostaurin. Treatment is given in stages. First comes induction treatment to try to bring the leukemia under control. After that, some participants may continue with more treatment, called consolidation, and later some may receive maintenance treatment to help keep the leukemia from coming back. In some cases, a stem cell transplant, also called HSCT, may be part of the care plan. The study follows participants through these treatment phases and checks for side effects and other health changes.

This is a Phase 1/2 study, which means it is an early study designed to find the best dose schedule and learn more about safety. It also looks at how many participants have no clear signs of leukemia left after treatment. The study is planned to run over several years.

The study is a Phase II trial, which means it is an earlier study that looks at how well the treatment works and how safe it is. It is open-label, so everyone knows which treatment is being given, and randomized, which means treatment is assigned by chance. The course of the study involves treatment with the study drugs over several cycles, with regular medical follow-up to watch for response and side effects. The study also checks for common and serious side effects and how long people remain free from worsening of the disease.

The purpose of this study is to find out if adding Revumenib to intensive chemotherapy helps people with this type of leukemia live longer without their disease getting worse compared to chemotherapy alone, and to see if this combination helps more people achieve complete remission with no detectable signs of cancer cells remaining in their bone marrow. During the study, participants will receive their assigned treatment and will be monitored regularly to check how well the treatment is working and to watch for any side effects. The study will track various outcomes including how long participants live, how long they remain in remission, and how many participants achieve complete remission with no measurable remaining disease.

The study will also carefully monitor the safety of the treatment by recording any unwanted effects that occur, checking blood test results regularly, and performing heart function tests and other examinations. Doctors will measure treatment success by looking at whether the cancer goes away completely, whether cancer cells can still be detected in the bone marrow or blood using special tests, and how long participants remain free of cancer. The study is expected to continue for several years to gather enough information about the long-term effects of this treatment combination.

The purpose of this study is to compare two different ways of giving venetoclax together with azacitidine. One group of people will take venetoclax for only seven days during each treatment cycle, while the other group will take venetoclax continuously for the full cycle of twenty-eight days. Both groups will receive azacitidine. The study wants to find out if taking venetoclax for a shorter time works as well as taking it for the full cycle in terms of putting the leukemia into remission, which means reducing or eliminating the cancer cells. This will be measured by looking at whether people achieve complete remission or complete remission with incomplete recovery of the bone marrow during the first six treatment cycles.

During the study, people will receive their assigned treatment in repeated cycles. Each cycle lasts twenty-eight days, and people may continue treatment for multiple cycles depending on how well the treatment works and how well they tolerate it. The study will monitor how well the treatment controls the leukemia, how long people live, and what side effects occur. The study will also look at quality of life and how the different treatment schedules affect the need for blood transfusions, infections, and hospital stays. The total treatment period can last up to one hundred sixty-eight days for venetoclax and up to forty-two days for azacitidine.

The purpose of this study is to evaluate the safety and feasibility of using this specific combination of medications before receiving stem cells from a donor (called allogeneic stem cell transplantation). The treatment involves receiving these medications through different methods – some are given as tablets by mouth, while others are administered through an intravenous line directly into the bloodstream.

During the study, patients will receive a carefully planned sequence of treatments over several days. Treosulfan will be given for three days, Fludarabine for five days, and Venetoclax for seven days. After this preparation phase, patients will receive stem cells from their matched donor. The doctors will then monitor the patients’ progress and how well the transplanted cells are working in their body.

The treatment being tested is administered as a powder for infusion, which is delivered directly into a vein through intravenous use. During the study, participants will receive this medication to help researchers understand how it moves through the body and to monitor any potential side effects. This process allows for a closer look at how the drug behaves in patients with this specific form of cancer.

The research is designed for individuals who have been newly diagnosed with this cancer and are either older than 60 years of age or cannot undergo standard induction chemotherapy, which is the intensive initial treatment used to kill cancer cells. Participants in the study will take the oral medications as part of their treatment plan to see how well the drugs work to achieve a complete response, meaning the cancer cells are no longer detectable, and to monitor any side effects that may occur.

The research involves two different approaches to treatment. In the first approach, ziftomenib is used alongside a nonintensive therapy consisting of venetoclax and azacitidine. In the second approach, ziftomenib is combined with an intensive therapy known as 7+3, which includes cytarabine and daunorubicin hydrochloride. Some participants may receive a placebo instead of ziftomenib to allow for a comparison between the different treatment methods.

During the study, participants will receive their assigned medications through different methods, such as oral pills or intravenous administration, which is the delivery of medicine directly into a vein. The study will monitor how long patients live and the time until the disease begins to grow again. This process helps determine if adding the new drug to standard treatments improves the long-term outcomes for people with these specific genetic forms of leukemia.

The treatment being investigated consists of revumenib used together with a chemotherapy regimen called FLA. This chemotherapy combination includes the drugs cytarabine and fludarabine, which are administered through an intravenous line, meaning they are delivered directly into a vein. Revumenib is taken orally as either a tablet or an oral solution. The goal is to determine how many patients experience a reduction in cancer cells after receiving up to two cycles of this combined treatment.

The purpose of this study is to understand how these medications work together in the body and to assess their safety and effectiveness in treating AML. Participants in the study will take these medications over a period of time, and researchers will monitor how the drugs interact with each other and how well they work in treating the cancer. The study will also look at any side effects that may occur during the treatment.

Participants will be involved in different phases of the study, where the main focus will be on how the body processes the medications and the overall response to the treatment. The study aims to provide valuable information on the potential benefits and risks of using ASTX727 and Venetoclax together for treating AML.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

The purpose of this study is to determine whether adding Quizartinib to the standard combination of Venetoclax and Azacitidine improves survival rates compared to using just Venetoclax and Azacitidine alone. The medications are taken by mouth as tablets. During the study, patients will receive their assigned treatment combination in repeated cycles, and doctors will monitor how well the treatment works and how it affects the disease. The study will track various outcomes including how long patients live, how long they remain free from disease progression, whether the cancer responds to treatment, and how the treatment affects quality of life.

Throughout the study, doctors will perform regular tests to check the status of the leukemia and monitor for any side effects from the medications. Blood tests will be used to measure if there are any remaining cancer cells that cannot be seen under a regular microscope, which is checked using a method called next-generation sequencing. The study will also look at how often patients need blood or platelet transfusions and will gather information about healthcare resources used during treatment. Patients will be asked to complete questionnaires about their quality of life and daily functioning during the course of their treatment.

The purpose of the study is to see how well gilteritinib works at eliminating these remaining cancer cells that can be detected using a special laboratory test called PCR-NGS. During the study, patients will receive gilteritinib tablets by mouth for up to eight months. The medication will be given at a dose of up to 120 milligrams per day. Throughout the treatment period, doctors will monitor patients regularly to check if the remaining cancer cells have disappeared and to observe how patients respond to the medication.

The study will also examine several additional aspects, including what types of genetic changes might appear if the cancer comes back, how long the treatment works before any resistance develops, and whether certain characteristics of the cancer cells or the patient’s immune system can predict how well the treatment will work. Doctors will use various laboratory tests to analyze changes in cancer cells and to look for specific genetic markers that might be related to treatment response. The study will also investigate whether certain mutations present alongside the FLT3-ITD mutation, such as those in genes called DNMT3A, NPM1, TET2, ASXL1, and TP53, have any effect on how patients respond to treatment.

The purpose of the study is to evaluate how long patients remain free from their cancer coming back when they receive both azacitidine and ivosidenib together. The study will look at whether this combination of medications can help keep the cancer from returning for 24 months. During the study, patients will receive the combination treatment for up to 24 months. The study will monitor how well the treatment works and watch for any unwanted effects that might occur. Doctors will also check the blood and bone marrow regularly to see if there are any signs of the cancer returning.

Throughout the study, patients will have regular check-ups and tests to assess their health and the status of their disease. Blood tests will be performed to monitor organ function, including the kidneys and liver, and to check blood cell counts. The study will track various outcomes including how long patients survive without their cancer returning, overall survival rates, and whether any signs of disease can be detected in the blood or bone marrow using special laboratory tests. Any side effects or health problems that occur during treatment will be carefully recorded and evaluated according to standard medical classifications.

The medication being studied, RVU120, comes in the form of capsules that are taken by mouth. The treatment can be given either alone or combined with other medications, depending on how the patient was treated in their previous study. The maximum daily amount that can be given is 150 milligrams, and treatment may continue for up to 5 months.

During the study, doctors will monitor how well patients tolerate the medication by checking for any side effects or health problems that may occur. The study will track how long patients can continue taking the medication before they need to stop treatment for any reason. This helps researchers understand both the long-term safety and effectiveness of RVU120 in treating these types of cancer.

The treatments used in this study include several anti-cancer medications: cytarabine, daunorubicin, etoposide, cladribine, mitoxantrone, obinutuzumab, ibrutinib, venetoclax, and fludarabine. Some patients may also receive cyclophosphamide, busulfan, or treosulfan as part of their treatment. The medications are given either through intravenous infusion or as oral tablets, depending on the specific drug.

The main purpose of this study is to determine if less intensive treatment can be as effective as standard treatment in patients who show no signs of remaining disease after initial therapy. The study will monitor patients’ survival, side effects, and whether the disease returns after treatment. Participants will be followed for several years to evaluate the long-term effectiveness of these treatment approaches.

The purpose of this research is to determine if CART84 is safe to use and to find the most effective dose for treating these types of blood cancers. The treatment involves collecting immune cells from the patient, modifying them to target cancer cells, and then returning them to the patient through an intravascular infusion (delivery into a vein).

During the study, patients will receive the CART84 treatment and will be monitored for response to therapy and any side effects. After receiving CART84, some patients may proceed to receive a stem cell transplant from a matched donor. The study includes regular blood tests and bone marrow examinations to check how well the treatment is working.

The purpose of this research is to determine how well patients respond to the combination of gilteritinib with chemotherapy and how well they tolerate this treatment. During the study, participants will receive gilteritinib tablets taken by mouth along with the chemotherapy medications. The maximum daily dose of gilteritinib will be 120 mg, and the treatment may continue for up to 15 months.

The treatment will be given in courses, and doctors will monitor how the disease responds to the therapy. They will check if the cancer goes into remission (when cancer cells are no longer detected or are significantly reduced) and will track the overall health of participants throughout the study period. The study will also look at how long any positive treatment effects last and how the treatment affects patients’ quality of life.

The treatment involves taking these medications in cycles. Some participants will receive bleximenib along with venetoclax and azacitidine, while others will receive venetoclax and azacitidine with a placebo. This is a double-blind study, which means neither the participants nor the researchers will know which treatment group a participant is in until the study is completed.

The study will monitor how participants respond to treatment by tracking various health indicators and will assess whether the addition of bleximenib improves complete remission (when there are no detectable cancer cells) and overall survival in patients with this type of leukemia.

The study uses Lisaftoclax, which belongs to a group of medications that work by blocking a protein called BCL-2 that helps cancer cells survive. Azacitidine is a medication that affects how genes work in cancer cells. Patients will receive either Lisaftoclax or placebo tablets along with azacitidine injections. The treatment continues for several months, with regular check-ups to monitor the patient’s health and how well the treatment is working.

During the study, patients will take the medications according to a specific schedule. Lisaftoclax or matching placebo tablets are taken by mouth, while azacitidine is given as an injection either under the skin or into a vein. The maximum daily dose of Lisaftoclax is 600 milligrams, and azacitidine is given at 75 milligrams per square meter of body surface area.

Participants in the study will receive Bleximenib along with other AML-directed therapies. The study will be conducted in two main parts. The first part will focus on determining the best dose of Bleximenib to use. The second part will further evaluate the safety and tolerability of this combination treatment. The study will involve regular monitoring to check for any side effects and to ensure the safety of the participants.

The purpose of this study is to explore the potential benefits of Bleximenib in treating AML with specific genetic changes. The study will help researchers understand how well Bleximenib works in combination with other treatments and what side effects might occur. This information could be valuable in developing new treatment options for people with AML in the future.

The purpose of the study is to find the best dose of Liposomal Annamycin when used with Cytarabine and to confirm if this combination works better than the placebo with Cytarabine. Participants will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study is divided into two parts. In the first part, researchers will determine the optimal dose of Liposomal Annamycin. In the second part, they will test this dose against the placebo to see if it improves the rate of complete remission, which means the cancer is no longer detectable after one cycle of treatment.

Participants will be monitored closely throughout the study to assess the safety and tolerability of the treatment. The study will also look at how long the remission lasts, overall survival rates, and the possibility of undergoing a bone marrow transplant after achieving remission. The trial aims to provide valuable information that could lead to better treatment options for people with refractory or relapsed AML.

Participants in the study will receive CCS1477 in the form of a capsule taken by mouth. In some cases, it will be combined with other medications, such as Dexamethasone or Pomalidomide. The trial will monitor the safety and tolerability of these treatments, which means checking for any side effects and how well patients can handle the medication. The study will also look at how the drug is processed in the body and its potential effects on the cancer.

The trial will take place over several years, with regular check-ups and assessments to track the progress of the treatment. This includes looking at changes in the cancer through various tests and evaluations. The goal is to gather information on the drug’s safety and its impact on the cancer, which could help in developing new treatment options for these serious conditions.

The purpose of the study is to determine if adding venetoclax to the treatment with ivosidenib and azacitidine can improve outcomes for patients with newly diagnosed IDH1-mutated AML who are not eligible for intensive chemotherapy. The study will involve taking these medications in the form of film-coated tablets or injections over a period of time. Some patients will receive a placebo, which looks like the real medication but does not contain the active drug, to compare the effects.

Participants in the study will be monitored to see how their condition responds to the treatment. The study will track how long patients remain free of disease progression, as well as other factors like overall survival and quality of life. The trial aims to provide valuable information on whether this combination of medications can offer a new treatment option for patients with this specific type of AML.

The purpose of the study is to evaluate how effective Ivosidenib is in improving the time patients remain free from events like disease relapse or death. Participants in the study will receive Ivosidenib as a maintenance therapy for up to 24 months after undergoing a procedure called allogeneic stem cell transplantation (alloSCT), which involves receiving healthy stem cells from a donor. The study will compare the outcomes of patients taking Ivosidenib with those who do not receive this treatment.

Throughout the study, participants will be monitored for various outcomes, including their overall survival and the rate at which they remain free from disease events. The study will also track any side effects or complications that may arise from the treatment. This research aims to provide valuable insights into the potential benefits of Ivosidenib for patients with AML or HR-MDS who have the IDH1 mutation.

Participants in the study will receive an infusion of RNK001 natural killer cells, which are specially prepared outside the body, and may also receive aldesleukin to help boost the immune response. The study will be conducted in two phases. In the first phase, the focus will be on assessing the safety and any side effects of the treatment. In the second phase, the study will look at how well the treatment works in controlling the disease.

The treatment involves a non-myeloablative immunosuppressive conditioning regimen, which means it is designed to suppress the immune system without completely destroying the bone marrow. This approach helps the body accept the new cells. The study will monitor participants closely to understand how the treatment affects their condition and to ensure their safety throughout the process. The trial aims to provide insights into the potential benefits of combining RNK001 and aldesleukin for patients with AML and related conditions.

The purpose of the study is to evaluate the effectiveness of a combination of medications used during the transplantation process. The medications being studied are Fludarabine, Treosulfan, and Melphalan. Fludarabine is used in combination with either Treosulfan or Melphalan to prepare the body for the transplant. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will compare the outcomes of using Treosulfan versus Melphalan in combination with Fludarabine to see which is more effective in helping patients with AML and MDS.

Participants in the study will receive one of the two treatment combinations and will be monitored for their response to the treatment. The study will also look at the prevention of a condition called Graft-versus-Host Disease (GvHD), which can occur after a transplant when the donor cells attack the recipient’s body. The study aims to find the best treatment approach to improve survival rates and reduce complications for patients undergoing allogeneic transplantation for AML and MDS.

The purpose of the study is to determine if this combination of medications can help improve the overall survival of patients with this specific type of AML. Participants in the study will receive either the combination of Revumenib, Azacitidine, and Venetoclax or a placebo along with Azacitidine and Venetoclax. The study will last for a period of up to 76 weeks, during which the effects of the treatment will be monitored. The medications will be administered in the form of tablets taken orally, and Azacitidine will be given as an injection.

This trial aims to provide valuable information on whether the addition of Revumenib can enhance the effectiveness of the existing treatment for patients with these specific genetic changes in AML. The study will also look at various outcomes, such as the time it takes for the treatment to start working, the duration of the response, and the quality of life of the participants. The results will help in understanding the potential benefits and safety of this new treatment approach for patients with AML who cannot undergo intensive chemotherapy.

The purpose of the study is to evaluate how effective this combination treatment is for elderly patients who have been newly diagnosed with AML and are eligible for a procedure called allogeneic stem cell transplantation. This procedure involves replacing diseased bone marrow with healthy stem cells from a donor. The study aims to see how many patients can successfully undergo this procedure after receiving the combination treatment.

Participants in the study will receive the combination of Venetoclax and Decitabine over a period of time. The study will monitor the patients’ response to the treatment and their ability to proceed to the stem cell transplantation. The trial will also observe the long-term outcomes of the transplantation, including any complications and the overall survival of the patients. The study is expected to continue until 2025.

The purpose of this research is to determine how effective Gemtuzumab Ozogamicin is when used together with standard chemotherapy in treating patients who have not received previous treatment for their AML. The study specifically looks at how well this combination reduces the number of cancer cells that remain in the body after treatment.

During the study, participants receive the medications through an intravenous infusion (given directly into a vein). The treatment consists of multiple phases, including initial treatment (induction) and additional treatment to maintain results (consolidation). Patients will be monitored for approximately 24 months to evaluate how well the treatment works and to check for any side effects.

The study is testing a treatment called Pentaglobin, which is a solution containing different types of proteins called immunoglobulins. These proteins are part of the immune system and help the body fight infections. The purpose of the study is to see if adding Pentaglobin early in the treatment can reduce the risk of death and improve survival rates in these patients. The study will compare the effects of Pentaglobin with the best available antimicrobial therapy, which is the standard treatment for infections.

Participants in the study will receive Pentaglobin through an infusion, which means it will be given directly into the bloodstream. The treatment will be administered for a maximum of three days. The study will monitor the patients for several months to see how well they respond to the treatment and to check for any side effects. The goal is to find out if Pentaglobin can help improve the outcomes for patients with febrile neutropenia who are at high risk due to these resistant bacteria.

The purpose of the study is to see how effective Quizartinib is when used alongside these standard chemotherapy treatments. Participants will receive either Quizartinib or a placebo in combination with chemotherapy during the initial treatment phase, known as induction, and the follow-up phase, known as consolidation. After these phases, participants will continue to receive Quizartinib or placebo as a maintenance therapy for up to 36 cycles, which helps to keep the cancer from returning. The study will monitor participants over time to see how long they live and how well they respond to the treatment.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to provide valuable information on whether adding Quizartinib to standard chemotherapy can improve outcomes for patients with newly diagnosed FLT3-ITD negative AML. This research could potentially lead to better treatment options for people with this type of leukemia.

Participants in the study will receive the medications Fludarabine and Treosulfan through an infusion, which is a method of delivering medication directly into the bloodstream. The study will also involve the use of other medications, such as Ciclosporin, Mycophenolic Acid, Methotrexate Sodium, and Anti-T Lymphocyte Immunoglobulin, which are used to support the treatment and help prevent complications. These medications are given to help the body accept the new stem cells and to reduce the risk of the cancer returning.

The study will follow participants over a period of time to monitor their health and the effectiveness of the treatment. The main goal is to see how well patients do one year after receiving the stem cell transplant, specifically looking at whether they remain free of leukemia. This research aims to provide valuable information on how to improve treatment options for people with AML.

The purpose of the study is to find a safe dose of the vaccine and to see if it can improve the chances of staying free from AML for a year after the first vaccination. The study is divided into two parts. In the first part, the focus is on determining the safest dose of the vaccine. In the second part, the goal is to see if the vaccine can increase the number of patients who remain free from AML by 20% compared to past patients who did not receive the vaccine. Participants will receive the vaccine through an injection into a vein, and the study will monitor them for any side effects and the effectiveness of the treatment over a period of time.

Throughout the study, researchers will also look at other important factors, such as the overall survival rate of participants and any changes in the immune system’s response to the WT1 protein. The study aims to provide valuable information on whether this new vaccine can be a beneficial treatment option for young patients with AML.

During the trial, participants will receive the medication AB8939 to see how their bodies react to it and to determine the best dose to use in future studies. Another medication, Vidaza, which contains the active substance Azacitidine, may also be used in the study. Vidaza is a powder that is mixed into a suspension for injection and is used to treat certain types of blood disorders. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will monitor participants over a period of time to observe any side effects and to measure how well the treatment works in controlling the disease. The goal is to find the most effective and safe dose of AB8939 for patients with these conditions. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather important information about the treatment’s effects.

The main purpose of this study is to find the best treatment combination and dosing for children with these blood cancers. The study will compare different chemotherapy combinations and evaluate how well they work in treating the disease. It will also test different ways of preparing patients for stem cell transplantation, a procedure that replaces damaged bone marrow with healthy cells.

The study will track how patients respond to treatment by monitoring their blood and bone marrow. Researchers will look at how long patients stay free of disease, how well they tolerate the treatments, and any side effects that may occur. The study will continue to follow patients for up to 10 years to understand the long-term effects of these treatments.

The purpose of the study is to determine which treatment approach provides better outcomes for patients with AML. Participants will be randomly assigned to receive either low-intensity therapy or high-dose chemotherapy. The study will monitor the time it takes for the disease to progress or for any complications to arise, as well as overall survival rates and response to treatment. Patients will also report on their quality of life during the study.

The trial will last several years, with an estimated end date in 2028. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments. The study will also track any side effects experienced by participants. This information will help doctors understand which treatment options may be most beneficial for patients with AML in the future.

Participants in the study will have been receiving a combination of Azacitidine and Venetoclax for about a year. The study will observe what happens when these medications are gradually reduced and eventually stopped. Researchers will monitor the participants’ health to see how long they remain free of the disease after stopping the treatment. This period is known as Disease-Free Survival. The study will also look at other factors, such as the duration of the response to treatment and overall survival.

Throughout the study, participants will be regularly checked to ensure their health and safety. The study aims to gather information that could help improve future treatment strategies for patients with acute myeloid leukemia. By understanding how patients respond to the discontinuation of these medications, researchers hope to find ways to maintain health and quality of life without continuous treatment.

Participants in the study will receive Ziftomenib in the form of a hard capsule taken by mouth, along with chemotherapy. The study will also include a group receiving a placebo, which is a substance with no active medication. The trial aims to determine the safety and how the body processes Ziftomenib, as well as to observe any side effects. The study will monitor participants over a period of time to assess the effectiveness of the treatment and any potential improvements in their condition.

The trial is designed for children who have experienced a return of their leukemia or whose leukemia has not responded to previous treatments. The study will help researchers understand how well Ziftomenib works in combination with chemotherapy and will provide important information about its safety and potential benefits for treating these types of leukemia in children. The estimated completion date for the study is the end of 2028.